AU3948602A - Combination radiation therapy and chemotherapy in conjuction with administrationof growth factor receptor antibody - Google Patents

Combination radiation therapy and chemotherapy in conjuction with administrationof growth factor receptor antibody

Info

Publication number
AU3948602A
AU3948602A AU3948602A AU3948602A AU3948602A AU 3948602 A AU3948602 A AU 3948602A AU 3948602 A AU3948602 A AU 3948602A AU 3948602 A AU3948602 A AU 3948602A AU 3948602 A AU3948602 A AU 3948602A
Authority
AU
Australia
Prior art keywords
administrationof
conjuction
chemotherapy
growth factor
radiation therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU3948602A
Inventor
Donald J Buchsbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alabama at Birmingham Research Foundation
Original Assignee
University of Alabama at Birmingham Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US25178700P priority Critical
Application filed by University of Alabama at Birmingham Research Foundation filed Critical University of Alabama at Birmingham Research Foundation
Priority to PCT/US2001/046179 priority patent/WO2002045653A2/en
Publication of AU3948602A publication Critical patent/AU3948602A/en
Application status is Pending legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
AU3948602A 2000-12-08 2001-12-07 Combination radiation therapy and chemotherapy in conjuction with administrationof growth factor receptor antibody Pending AU3948602A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US25178700P true 2000-12-08 2000-12-08
PCT/US2001/046179 WO2002045653A2 (en) 2000-12-08 2001-12-07 Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody

Publications (1)

Publication Number Publication Date
AU3948602A true AU3948602A (en) 2002-06-18

Family

ID=22953402

Family Applications (1)

Application Number Title Priority Date Filing Date
AU3948602A Pending AU3948602A (en) 2000-12-08 2001-12-07 Combination radiation therapy and chemotherapy in conjuction with administrationof growth factor receptor antibody

Country Status (3)

Country Link
US (2) US20020076408A1 (en)
AU (1) AU3948602A (en)
WO (1) WO2002045653A2 (en)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
RU2294761C2 (en) * 1999-05-14 2007-03-10 Имклон Систимс Инкопэритид Method for treating resistant human tumors with epidermis growth factor receptors antagonists
CA2407556C (en) * 2000-05-19 2011-06-21 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
WO2002011677A2 (en) * 2000-08-09 2002-02-14 Imclone Systems Incorporated Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
ES2372694T3 (en) * 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Tyrosine kinase inhibitors imidazo [1,5-a] pyrazine.
ZA200606557B (en) * 2004-02-06 2008-02-27 Elan Pharm Inc Methods and compositions for treating tumors and metastatic disease
MXPA06010715A (en) * 2004-03-19 2007-05-23 Imclone Systems Inc Human anti-epidermal growth factor receptor antibody.
AU2005230818B2 (en) * 2004-04-02 2010-11-25 Osi Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
MXPA06014002A (en) * 2004-06-03 2007-02-08 Hoffmann La Roche Treatment with cisplatin and an egfr-inhibitor.
WO2005117877A1 (en) * 2004-06-03 2005-12-15 F.Hoffmann-La Roche Ag Treatment with irinotecan (cpt-11) and an egfr-inhibitor
KR100986945B1 (en) * 2004-06-03 2010-10-12 에프. 호프만-라 로슈 아게 Treatment with gemcitabine and an egfr-inhibitor
KR100851271B1 (en) * 2004-06-03 2008-08-08 에프. 호프만-라 로슈 아게 Treatment with irinotecan cpt-11 and an egfr-inhibitor
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
BRPI0808418A2 (en) 2007-03-02 2014-07-22 Genentech Inc Prediction of response to a HER inhibitor
US9551033B2 (en) * 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) * 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
WO2009091939A1 (en) * 2008-01-18 2009-07-23 Osi Pharmaceuticals, Inc. Imidazopyrazinol derivatives for the treatment of cancers
ES2396613T3 (en) * 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopyrazines and replaced imidazotriazinas
WO2010107968A1 (en) 2009-03-18 2010-09-23 Osi Pharmaceuticals, Inc. Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
CN104447995A (en) 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 Bispecific anti-HER antibodies
WO2010123792A1 (en) 2009-04-20 2010-10-28 Osi Pharmaceuticals, Inc. Preparation of c-pyrazine-methylamines
EP2427192A1 (en) * 2009-05-07 2012-03-14 OSI Pharmaceuticals, LLC Use of osi-906 for treating adrenocortical carcinoma
JP5705836B2 (en) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Modulators for her2 signaling gastric cancer patients expressing Her2
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
WO2011103242A1 (en) 2010-02-18 2011-08-25 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
CN103890007A (en) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 Neuregulin antibodies and uses thereof
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
US20130195870A1 (en) 2011-11-30 2013-08-01 Genentech, Inc. ERBB3 Mutations In Cancer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
MX2014011500A (en) 2012-03-27 2014-12-05 Genentech Inc Diagnosis and treatments relating to her3 inhibitors.
BR112015012644A2 (en) 2012-11-30 2017-12-19 Hoffmann La Roche Method for determining the need for a patient with cancer, cancer treatment method, pharmaceutical composition, use of a nucleic acid or antibody and kit;
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20004224A3 (en) * 1998-05-15 2002-02-13 Imclone Systems Incorporated Non-radiolabelled inhibitor of protein tyrosine kinase receptor
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US6767541B2 (en) * 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways

Also Published As

Publication number Publication date
WO2002045653A2 (en) 2002-06-13
US20050281814A1 (en) 2005-12-22
US20020076408A1 (en) 2002-06-20
WO2002045653A3 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
GB2382985B (en) Headrest with wing members
GB2378443B (en) Pyrazole derivatives and their use as gastrin and cholecystokin in receptor ligands
TWI339209B (en) Human antibodies that bind human il-12 and methods for producing
GB2366800B (en) Antibody molecules having specificity for human tumor necrosis factor alpha,and use thereof
EP2940044B8 (en) Anti-tnf alpha antibodies for use in therapy
AU7287901A (en) Secure and reliable document delivery
IL193149A (en) Anti il-17c antibody and therapeutic compositions comprising same
HK1034440A1 (en) Absorbent article and absorbent interlabial device with substance thereon for maintaining the article and device in position
PL361842A1 (en) Aminothiazoles and their use as adenosine receptor antagonists
HRP20060251B1 (en) Substituted oxasolidinones and their use
EP1333858B8 (en) Vaccines with enhanced immune response and methods for their preparation
EP1212452A4 (en) Methods for encoding and sorting in vitro translated proteins
PT885002E (en) Materials and methods for enhancing cellular internalization
AU5741001A (en) Epitope synchronization in antigen presenting cells
IL221508D0 (en) Use of a naked class i anti-cea monoclonal antibody in the preparation of a pharmaceutical composition for treating a cea and or nca expressing cancer
ZA200105311B (en) Indole derivatives and their use as MCP-1 antagonists.
HK1065724A1 (en) An antibody specific for soluble baff for use in the treatment of cancer
AU2003239968A1 (en) Imaging volumes with arbitrary geometries in contact and non-contact tomography
IL179476D0 (en) Antibodies against human interleukin-13 and uses therefor
AU2002315306A1 (en) Combination therapy using anti-EGFR antibodies and anti-hormonal agents
GB2382330B (en) Improvements in and relating to road and rail tankers
AU2002332290A1 (en) Recombinant anti-osteopontin antibody and use thereof
PL361887A1 (en) 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
IL146950D0 (en) Recombinant anti-cd40 antibody and uses thereof
IL139285D0 (en) Peg-lhrh analog conjugates, their preparation and use